title: CE: early localized prostate cancer.
abstract: As many as 233,000 men in the United States are diagnosed with prostate cancer each year. Most diagnoses are of low-grade, localized disease, which tends to be slow growing and is rarely lethal, even in the absence of intervention. The amount and complexity of the information men receive at diagnosis may be overwhelming and difficult to process, particularly given the weight of a new cancer diagnosis and the potential for long-term, life-altering adverse effects from treatment. This review examines the multiple options available for men with newly diagnosed, low-risk, localized prostate cancer and explains how nurses can help these men and their partners make treatment decisions that are appropriate for their particular circumstances.
authors: Anne Katz is a certified sexuality counselor at CancerCare Manitoba, a clinical nurse specialist at the Manitoba Prostate Centre, and a faculty member in the College of Nursing at the University of Manitoba, Winnipeg, Canada, and Athabasca University, Alberta, Canada. She is also the editor of Oncology Nursing Forum. Contact author: anne.katz@cancercare.mb.ca. The author and planners have disclosed no potential conflicts of interest, financial or otherwise.
authors: Anne
authors: A
authors: Katz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D003479:Curriculum; D055088:Early Detection of Cancer; D004509:Education, Nursing, Continuing; D006801:Humans; D008297:Male; D008875:Middle Aged; D024802:Nurse's Role; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D012306:Risk; D014481:United States
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen